Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy
- 17 May 2022
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (23), 5030-5039
- https://doi.org/10.1158/1078-0432.ccr-21-2390
Abstract
Immunotherapy targeting co-inhibitory receptors has been highly successful in treating a wide variety of malignancies, however only a subset of patients exhibits durable responses. The first FDA-approved immunotherapeutics targeting co-inhibitory receptors PD1 and CTLA4, alone or in combination, significantly improved survival but were also accompanied by substantial toxicity in combination. The third FDA-approved immune checkpoint inhibitor targets LAG3, a co-inhibitory receptor expressed on activated CD4+ and CD8+ T cells, especially in settings of long-term antigenic stimulation, such as chronic viral infection or cancer. Mechanistically, LAG3 expression limits both the expansion of activated T cells and the size of the memory pool, suggesting that LAG3 may be a promising target for immunotherapy. Importantly, the mechanism(s) by which LAG3 contributes to CD8+ T cell exhaustion may be distinct from those governed by PD1, indicating that the combination of anti-LAG3 and anti-PD1 may synergistically enhance antitumor immunity. Clinical studies evaluating the role of anti-LAG3 in combination with anti-PD1 are underway, and recent phase III trial results in metastatic melanoma demonstrate both the efficacy and safety of this combination. Further ongoing clinical trials are evaluating this combination across multiple tumor types and the adjuvant setting, with accompanying translational and biomarker-focused studies designed to elucidate the molecular pathways that lead to improved antitumor T cell responses following dual blockade of PD1 and LAG3. Overall, LAG3 plays an important role in limiting T cell activation and has now become part of the repertoire of combinatorial immunotherapeutics available for the treatment of metastatic melanoma.Keywords
Funding Information
- National Cancer Institute (R35 CA263850)
- National Cancer Institute (P50 CA254865)
- National Cancer Institute (CA047904)
- National Institute of Allergy and Infectious Diseases (P01 AI108545)
- National Institute of Allergy and Infectious Diseases (R01 AI144422)
This publication has 79 references indexed in Scilit:
- Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cellsNature Medicine, 2013
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to ApoptosisThe Journal of Immunology, 2011
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4European Journal of Immunology, 2010
- High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated Immunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free SurvivalThe Journal of Molecular Diagnostics, 2010
- LAG-3 Regulates Plasmacytoid Dendritic Cell HomeostasisThe Journal of Immunology, 2009
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- Metalloproteases regulate T-cell proliferation and effector function via LAG-3The EMBO Journal, 2007
- Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cellsEuropean Journal of Immunology, 2005